Last reviewed · How we verify
SyB C-1101
At a glance
| Generic name | SyB C-1101 |
|---|---|
| Sponsor | SymBio Pharmaceuticals |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Pharmacokinetics Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS) (PHASE1)
- Combination Therapy of SyB C-1101 and Azacytidine in Patients With Myelodysplastic Syndrome (PHASE1)
- Study of SyB C-1101 in Patients With Myelodysplastic Syndrome (PHASE1)
- Long Term Safety Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS) - Extension Study (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |